KRAS and pancreatic adenocarcinoma: For KRAS, under more restrictive assumptions, we observed evidence for a trade-off between functional and immune fitness for hotspot mutations in pancreatic adenocarcinoma, where KRAS is typically mutated (Extended Data Fig. 4e and Supplementary Methods).